Sagimet Biosciences reports data from Phase 3 trial on denifanstat

Sagimet Biosciences (SGMT) reported that data from a Phase 3 clinical trial for the treatment of moderate to severe acne vulgaris conducted by Sagimet’s license partner Ascletis Bioscience will be presented at the European Academy of Dermatology and Venerology, EADV, 2025 Congress taking place September 17-20, 2025 in Paris, France. Denifanstat is a once-daily oral small molecule fatty acid synthase, FASN, inhibitor being developed by Ascletis as ASC40 for acne in China and by Sagimet for MASH in the rest of world. Key Presentation Highlights: Once daily 50 mg denifanstat achieved highly statistically significant and clinically meaningful improvements across all efficacy endpoints. In particular, denifanstat showed 18.6% placebo-adjusted increase in treatment success rate, 22.0% placebo-adjusted reduction in total lesions and 20.2% placebo-adjusted reduction in inflammatory lesions. Denifanstat was also generally well-tolerated.